THERAPY DOSSIER · th-2d27cae94047

Injectable optimised acellular (iOA) peripheral nerve hydrogel

Device

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29380749 ↗2018Mixed findings

Injectable hydrogels of optimized acellular nerve for injection in the injured spinal cord.

RatSpinal cord injuryContusionSprague Dawleyn = Six animals per injection group (PBS and iOA), from startin…Intraspinal injection into the lesion using a 34 gauge needle6 microlitres injected at 1 microlitre per minute; hydrogel…One week after injury

Model: Unilateral cervical contusion spinal cord injury; laminectomy at C3/C4 and Infinite Horizon impactor, 2.5 mm tip, 200 kDyn set force

iOA shifted the M1:M2 macrophage ratio from 1.88 to 0.635 and increased distal axonal coverage at eight weeks but gave no locomotor or respiratory functional benefit and no change in glial scarring or spared tissue.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.92. Machine-extracted fields require source verification.

Loading the evidence…